5-HT2C receptor modulation and the treatment of obesity

被引：36
作者：
Bickerdike, MJ [1 ]
Vickers, SP [1 ]
Dourish, CT [1 ]
机构：
[1] Cerebrus PLC, Wokingham RG41 5UA, England
来源：
DIABETES OBESITY & METABOLISM | 1999年 / 1卷 / 04期
关键词：
D O I：
10.1046/j.1463-1326.1999.00037.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：207 / 214
页数：8
相关论文
共 50 条
  • [21] Synthesis and biological evaluation of novel, selective 5-HT2C receptor agonists for the treatment of obesity.
    Robichaud, AJ
    Chen, WT
    McClung, C
    Clark, D
    Deng, W
    Brondyke-Calvello, E
    Mitchell, IS
    Lee, TY
    Rajagopalan, P
    Fitzgerald, LW
    Conklin, DS
    McElroy, JF
    Rohrbach, KW
    Miller, KJ
    Largent, BL
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U19 - U19
  • [22] 5-HT2C Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators
    Przegalinski, Edmund
    Witek, Kacper
    Wydra, Karolina
    Kotlinska, Jolanta H.
    Filip, Malgorzata
    [J]. NUTRIENTS, 2023, 15 (06)
  • [23] A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment
    Palacios, Jose M.
    Pazos, Angel
    Hoyer, Daniel
    [J]. PSYCHOPHARMACOLOGY, 2017, 234 (9-10) : 1395 - 1418
  • [24] New 5-HT2c receptor agonists
    Bishop, MJ
    Nilsson, BM
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2003, 13 (11) : 1691 - 1705
  • [25] Imaging the 5-HT2C receptor with PET: Evaluation of 5-HT2C and 5-HT2A affinity of pimavanserin in the primate brain
    Ridler, Khanum
    Rizzo, Gaia
    Burstein, Ethan S.
    Forsberg Moren, Anton
    Stepanov, Vladimir
    Halldin, Christer
    Rabiner, Eugenii A.
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2025, 45 (02) : 352 - 364
  • [26] Evaluation of selective 5-HT2c phenylpiperazine agonists for the treatment of obesity.
    Tsai, JH
    Smith, BM
    Chen, R
    Prieto, E
    Park, D
    Smith, J
    Schultz, JA
    Gallardo, C
    Estrada, S
    Fang, S
    Gilson, C
    Thomsen, W
    Saldana, H
    Bjenning, C
    Creehan, K
    Gonzalez, L
    Whelan, K
    Webb, RR
    Beeley, N
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U113 - U113
  • [27] Chronic treatment with SSRIs desensitizes both 5-HT2A and 5-HT2C receptor function
    Yamauchi, Miki
    Miyara, Takako
    Matsushima, Tetsuya
    Tatebayashi, Tomoko
    Yokoyama, Fumikazu
    Onozawa, Kaname
    Yoshida, Akiko
    Imanishi, Taiichiro
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 101 : 84 - 84
  • [28] Synthesis and biological evaluation of novel, selective 5-HT2C receptor agonists for obesity
    Lee, T
    Robichaud, AJ
    Chen, WT
    Lu, YM
    Dowdell, S
    Boyle, KE
    Mitchell, IS
    Fevig, JM
    Wexler, RR
    Miller, KJ
    Largent, BL
    Rohrbach, KW
    Devenny, JJ
    McElroy, JF
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U158 - U159
  • [29] From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists
    Higgins, Guy A.
    Sellers, Edward M.
    Fletcher, Paul J.
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2013, 34 (10) : 560 - 570
  • [30] Discovery and development of 5-HT2C receptor agonists for obesity: is there light at the end of the tunnel?
    Miller, Keith J.
    Wacker, Dean A.
    [J]. FUTURE MEDICINAL CHEMISTRY, 2010, 2 (12) : 1761 - 1775
12345